secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108804
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones
--------------------------------------------------------------------------------

- Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.
- Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.
- Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.
- MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/0001104659-25-108804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/mgtx-20251107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer